3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
189
Neoplasm Metastasis
19
Neoplasms
9
Ovarian Neoplasms
8
Breast Diseases
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Neoplasms by Site
3
Lung Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Neoplasm, Residual
2
Multiple Myeloma
2
Melanoma
2
Inflammation
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Estrogen Receptor-positive Breast Cancer
2
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
palbociclib
×
Breast
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled